2) Rajkumar SV, Dimopoulos MA, Palumbo A et al : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15 : e538-e548, 2014
3) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma : an overview of 6, 633 patients from 27 randomized trials. Myeloma Trialists'Collaborative Group. J Clin Oncol 16 : 3832-3842, 1998
4) Sonneveld P, Goldschmidt H, Rosifiol L et al : Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma : a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 31 : 3279-3287, 2013
5) Alexanian R, Barlogie B, Dixon D : High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 105 : 8-11, 1986
6) Alexanian R, Dimopoulos MA, Delasalle K et al : Primary dexamethasone treatment of multiple myeloma. Blood 80 : 887-890, 1992
7) Smith A, Wisloff F, Samson D et al, Nordic Myeloma Study Group, British Committee for Standards in Haematology : Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 132 : 410-451, 2006
8) Gay F, Oliva S, Petrucci MT et al : Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma : a randomised, multicentre, phase 3 trial. Lancet Oncol 16 : 1617-1629, 2015
9) Attal M, Lauwers-Cances V, Hulin G et al : Autologous transplantation for multiple myeloma in the era of new drugs : A phase III study of the Intergroup Francophone Du Myelome (IFM/DFCI 2009 Trial). Blood 126 : 391, 2015
10) 日本骨髄腫学会編 : 多発性骨髄腫の診療指針 第4版, 文光堂, 東京, 2016
11) NCCN Clinical Practice Guideline in Oncology. Multiple myeloma version 3. 2017. (https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf)
12) San Miguel JF, Schlag R, Khuageva NK et al : Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 31 : 448-455, 2013
13) Facon T, Dimopoulos M, Dispenzieri A et al : Final Analysis of Overall Survival from the First Trial. Blood 128 : 241, 2016
14) Durie BG, Hoering A, Abidi MH et al : Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777) : a randomised, open-label, phase 3 trial. Lancet 389 : 519-527, 2017
15) San Miguel J, Weisel K, Moreau P et al : Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003) : a randomised, open-label, phase 3 trial. Lancet Oncol 14 : 1055-1066, 2013
16) San-Miguel JF, Hungria VT, Yoon SS et al : Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma : a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15 : 1195-1206, 2014
17) Lonial S, Dimopoulos M, Palumbo A et al : Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 373 : 621-631, 2015
18) Stewart AK, Rajkumar SV, Dimopoulos MA et al : Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372 : 142-152, 2015
19) Moreau P, Masszi T, Grzasko N et al : Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 374 : 1621-1634, 2016
20) Dimopoulos MA, Oriol A, Nahi H et al : Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 375 : 1319-1331, 2016
21) Palumbo A, Chanan-Khan A, Weisel K et al : Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 375 : 754-766, 2016